Results 201 to 210 of about 46,379 (288)

Multidisciplinary Oral Rehabilitation in Osteogenesis Imperfecta: 18‐Year‐Old Case Report

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder characterized by bone fragility and Type I collagen defects. Although dentinogenesis imperfecta (DI) is a classic manifestation, patients with OI may experience significant dental deterioration even in its absence due to inherent dentinal weakness.
Pegah Mosannen Mozafari   +3 more
wiley   +1 more source

Langerhans Cell Histiocytosis in Adults: A Canadian Multicenter Case Series

open access: yesHematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Langerhans cell histiocytosis (LCH) is a rare clonal myeloid neoplasm. Canadian data on clinical characteristics, molecular profile, and treatment outcomes is limited. This study aims to report the initial experience of a Canadian rare diseases program, reflecting “real‐world” diagnostic pathways, referral patterns, and treatment heterogeneity
Stephanie Quon   +7 more
wiley   +1 more source

Applications of Mesenchymal Stromal Cells for Treatment of Diseases

open access: yesMedComm, Volume 7, Issue 9, September 2026.
This schematic summarizes the major therapeutic mechanisms of MSCs across different disease systems and highlights factors associated with MSCs dysfunction, together with current strategies to enhance MSCs function and therapeutic efficacy. This summary diagram illustrates that MSCs exert therapeutic effects in various diseases through multiple ...
Dongmei Xue, Yongsheng Li, Lei Wu
wiley   +1 more source

Epitranscriptomic Regulation of Bone Metabolism: Emerging Roles of N6‐Methyladenosine (m6A) Modification in Skeletal Homeostasis

open access: yesOral Science International, Volume 23, Issue 3, September 2026.
ABSTRACT N6‐methyladenosine (m6A) is the most abundant internal chemical modification of eukaryotic RNA and a central mechanism of epitranscriptomic gene regulation. Although m6A was first characterized in messenger RNA (mRNA), it is also deposited on ribosomal RNA (rRNA), circular RNA, and other RNA species, where it regulates RNA stability, decay ...
Shoichiro Kokabu, Quan Yuan
wiley   +1 more source

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers

open access: yesBritish Journal of Haematology, Volume 209, Issue 3, Page 1076-1084, September 2026.
Summary The Magnolia study demonstrated that continuation of zoledronic acid (ZOL) beyond 2 years reduces the risk of progressive bone disease (PBD) in patients with multiple myeloma (MM). This follow‐up study investigated the effects of ZOL in patients achieving very good partial response (VGPR) compared to patients who did not and whether bone ...
Michael Tveden Gundesen   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy